+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bladder Cancer Drugs Market Research Reports

From
From
Nonmuscle Invasive Bladder Cancer - Pipeline Insight, 2021 - Product Thumbnail Image

Nonmuscle Invasive Bladder Cancer - Pipeline Insight, 2021

  • Clinical Trials
  • July 2021
  • 80 pages
From
From
From
From
Bladder Cancer Treatment Drugs Companies in China - Product Thumbnail Image

Bladder Cancer Treatment Drugs Companies in China

  • Report
  • April 2021
  • 66 pages
From
Bladder Cancer Treatment Drugs Markets in China - Product Thumbnail Image

Bladder Cancer Treatment Drugs Markets in China

  • Report
  • April 2021
  • 235 pages
From
From
From
From
From
From
From
Loading Indicator

Bladder cancer is the fourth most common cancer among males in the US and due to its prevalence among the over 65s, diagnoses are set to increase in ageing populations worldwide. Reports in the Bladder Cancer section cover a variety of areas, such as the latest R&D and clinical trials taking place in universities, hospitals and other research centres around the world. Explore epidemiology, unmet needs, drug development (cytotoxic, immunotherapy agents, etc.), supply & demand, business development strategies, licensing and partnership opportunities, and the activities of key industry players such as Bristol-Myers Squibb, Spectrum Pharmaceuticals, Bioniche Life Sciences, Endo Pharmaceuticals, Eli Lilly and Sanofi-Aventis. Show Less Read more

adroll